Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-22-020153
Filing Date
2022-03-18
Accepted
2022-03-18 20:01:07
Documents
1
Period of Report
2022-03-16

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3723
  Complete submission text file 0001209191-22-020153.txt   5131
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Issuer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address
Ingalls Kerry D. (Reporting) CIK: 0001816804 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39376 | Film No.: 22753963